Advertisement

Index by author

A

  1. Abounader, Roger

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  2. Aldape, Kenneth

  3. Ames, Matthew M.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  4. Angagaw, Minilik H.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

B

  1. Babu, Boga Sobhana

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Batzler, Anthony

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  3. Bengtsson, Linnea

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  4. Bhat, Krishna P.L.

  5. Bishop, W. Robert

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  6. Black, Stuart

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

C

  1. Cairns, Rob A.

  2. Carlson, Erin E.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  3. Carr, Donna

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  4. Chang, Kyle

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  5. Chanock, Stephen J.

  6. Chen, Zhengming

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  7. Chiosea, Simion

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  8. Chung, Woonbok

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  9. Cooper, Alan

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  10. Cortez, Elsa

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  11. Costantino, Joseph P.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

D

  1. Daublain, Pierre

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Dayananth, Priya

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  3. Deng, Yongi

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  4. DePinho, Ronald A.

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  5. DeRose, Yoko S.

  6. Desai, Jagdish

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  7. Diergaarde, Brenda

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  8. DiNunzio, Edward

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  9. Dominguez, Charli L.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  10. Drummond, Jennifer

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  11. Du, Yu

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  12. Duvvuri, Umamaheswar

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

E

  1. Ekiz, Huseyin Atakan

  2. El-Naggar, Adel K.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  3. Eyob, Henok

F

  1. Fawell, Stephen

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Ferris, Robert L.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Flockhart, David A.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  4. Floyd, Desiree H.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  5. Foerster, Friedrich

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  6. Frederick, Mitchell J.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  7. Freilino, Maria

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

G

  1. Gao, Xiaolei

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Garraway, Levi A.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Gibbs, Richard A.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  4. Gilbert, Breean R.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  5. Gilliland, D. Gary

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  6. Goetz, Matthew P.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  7. Grandis, Jennifer R.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  8. Gutkind, J. Silvio

H

  1. Hammerman, Peter S.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  2. Harris, Thurl E.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  3. Hedberg, Matthew L.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  4. Hicklin, Daniel

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  5. Hruza, Alan

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

I

  1. Iglesias-Bartolome, Ramiro

  2. Ingle, James N.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  3. Issa, Jean-Pierre J.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  4. Ivanova, Elena

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

J

  1. Jayaraman, Lata

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Jenkins, Gregory D.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  3. Jha, Sharda

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  4. Jin, Weihong

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  5. Johnson, Jonas T.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

K

  1. Kefas, Benjamin A.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  2. Kelly, Joe

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  3. Kim, Seungwon

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  4. Kirschmeier, Paul

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  5. Kubo, Michiaki

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  6. Kwok-Shing Ng, Patrick

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

L

  1. Lee, Jae K.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  2. Li, Hua

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Liu, Debra

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  4. Liu, Jenny

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  5. Liu, Mohan

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  6. Long, Brian

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  7. Lu, Yiling

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  8. Lui, Vivian W.Y.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  9. Lutterbach, Bart A.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

M

  1. Machiela, Mitchell J.

  2. Mak, Tak W.

  3. Martin, Daniel

  4. Mills, Gordon B.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  5. Moorthy, Shhyam

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  6. Morris, Erick J.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  7. Mullins, Garrett R.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  8. Mushiroda, Taisei

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  9. Muzny, Donna M.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  10. Myers, Jeffrey N.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

N

  1. Nakamura, Yusuke

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  2. Neskey, David M.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  3. Nissan, Moriah H.

  4. Nukui, Tomoko

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

O

  1. Ortega Alves, Marcus V.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

P

  1. Paik, Ji-Hye

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  2. Paik, Soonmyung

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  3. Paliwal, Sunil

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  4. Pelletier, Marc R.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  5. Pendleton, Kelsey

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  6. Peyser, Noah D.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  7. Philippar, Ulrike

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  8. Pickering, Curtis R.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  9. Pinheiro, Elaine M.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  10. Protopopov, Alexei

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  11. Purow, Benjamin W.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

R

  1. Restaino, Clifford R.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Romkes, Marjorie

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Rosen, Neal

S

  1. Samatar, Ahmed A.

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Sauerwein, Sam

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Schaid, Daniel J.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  4. Seethala, Raja

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  5. Shin, Sandra J.

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  6. Shipps, Gerald

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  7. Siliphaivanh, Phieng

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  8. Solit, David B.

V

  1. Vangara, Bhavana S.

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  2. Vogel, Victor G.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

W

  1. Waltz, Susan E.

  2. Wang, James

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  3. Wang, Jing

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  4. Wang, Liewei

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  5. Wang, Lin

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  6. Weinshilboum, Richard M.

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  7. Weinstein, John N.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  8. Welm, Alana L.

  9. Wheeler, David A.

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  10. Wickerham, D. Lawrence

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  11. Williams, Matthew A.

  12. Wilson, Gabriela Mustata

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  13. Windsor, William

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  14. Witter, David

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  15. Wolmark, Norman

    1. Research Articles | AuthorChoice
      Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
      James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura and Richard M. Weinshilboum
      Cancer Discov July 1 2013 3 (7) 812-825; DOI:10.1158/2159-8290.CD-13-0038

      SNPs related to ZNF423 and CTSO are associated with breast cancer risk during SERM therapy, and these genes promote estrogen-dependent induction of BRCA1 transcription in an SNP-dependent fashion.

  16. Wu, Xifeng

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

X

  1. Xiao, Aizhen

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  2. Xiao, Dong

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Xiao, Li

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  4. Xiao, Yonghong

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  5. Xie, Tong-xin

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  6. Xin, Wenjun

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

Y

  1. Yacur, Melissa N.

    1. Research Articles
      Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
      Charli L. Dominguez, Desiree H. Floyd, Aizhen Xiao, Garrett R. Mullins, Benjamin A. Kefas, Wenjun Xin, Melissa N. Yacur, Roger Abounader, Jae K. Lee, Gabriela Mustata Wilson, Thurl E. Harris and Benjamin W. Purow
      Cancer Discov July 1 2013 3 (7) 782-797; DOI:10.1158/2159-8290.CD-12-0215

      Inhibition of diacylglycerol kinase α downregulates oncogenic pathways including HIF-1α and mTOR and is selectively toxic to glioblastoma and other cancer cells.

  2. Ying, Haoqiang

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  3. Yoo, Suk Young

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

Z

  1. Zawel, Leigh

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  2. Zeng, Yan

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  3. Zhang, Di

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  4. Zhang, Jiexin

    1. Research Articles | Free Article
      Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
      Curtis R. Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M. Neskey, Mei Zhao, Marcus V. Ortega Alves, Kyle Chang, Jennifer Drummond, Elsa Cortez, Tong-xin Xie, Di Zhang, Woonbok Chung, Jean-Pierre J. Issa, Patrick A. Zweidler-McKay, Xifeng Wu, Adel K. El-Naggar, John N. Weinstein, Jing Wang, Donna M. Muzny, Richard A. Gibbs, David A. Wheeler, Jeffrey N. Myers and Mitchell J. Frederick
      Cancer Discov July 1 2013 3 (7) 770-781; DOI:10.1158/2159-8290.CD-12-0537

      Gene expression, copy number, methylation, and mutation analyses implicate Notch deregulation in oral squamous cell carcinoma and identify potentially actionable events.

  5. Zhang, Ling

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  6. Zhang, Qiuhong

    1. Research Briefs | AuthorChoice
      Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
      Vivian W.Y. Lui, Matthew L. Hedberg, Hua Li, Bhavana S. Vangara, Kelsey Pendleton, Yan Zeng, Yiling Lu, Qiuhong Zhang, Yu Du, Breean R. Gilbert, Maria Freilino, Sam Sauerwein, Noah D. Peyser, Dong Xiao, Brenda Diergaarde, Lin Wang, Simion Chiosea, Raja Seethala, Jonas T. Johnson, Seungwon Kim, Umamaheswar Duvvuri, Robert L. Ferris, Marjorie Romkes, Tomoko Nukui, Patrick Kwok-Shing Ng, Levi A. Garraway, Peter S. Hammerman, Gordon B. Mills and Jennifer R. Grandis
      Cancer Discov July 1 2013 3 (7) 761-769; DOI:10.1158/2159-8290.CD-13-0103

      PI3K pathway mutations are found in 30.5% of head and neck squamous cell carcinomas and may indicate sensitivity to PI3K inhibitors.

  7. Zhang, Rumin

    1. Research Briefs
      Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
      Erick J. Morris, Sharda Jha, Clifford R. Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward DiNunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H. Angagaw, Elaine M. Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps, Alan Hruza, James Wang, Joe Kelly, Sunil Paliwal, Xiaolei Gao, Boga Sobhana Babu, Liang Zhu, Pierre Daublain, Ling Zhang, Bart A. Lutterbach, Marc R. Pelletier, Ulrike Philippar, Phieng Siliphaivanh, David Witter, Paul Kirschmeier, W. Robert Bishop, Daniel Hicklin, D. Gary Gilliland, Lata Jayaraman, Leigh Zawel, Stephen Fawell and Ahmed A. Samatar
      Cancer Discov July 1 2013 3 (7) 742-750; DOI:10.1158/2159-8290.CD-13-0070

      An ERK1/2 inhibitor with properties of both type I and type II kinase inhibitors suppresses MAPK signaling and proliferation in BRAF and MEK inhibitor-resistant cancer cells.

  8. Zhang, Yuqing

    1. Research Articles
      ZNF365 Promotes Stability of Fragile Sites and Telomeres
      Yuqing Zhang, Sandra J. Shin, Debra Liu, Elena Ivanova, Friedrich Foerster, Haoqiang Ying, Hongwu Zheng, Yonghong Xiao, Zhengming Chen, Alexei Protopopov, Ronald A. DePinho and Ji-Hye Paik
      Cancer Discov July 1 2013 3 (7) 798-811; DOI:10.1158/2159-8290.CD-12-0536

      ZNF365 is a p53-inducible gene product that maintains genomic stability by preventing recombination of defective telomere ends and common fragile site abnormalities.

  9. Zhao, Mei